alexa Abstract | The Origin of Nanotoxicity: Physical Damage

Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article Open Access


Now safety concern of in vivo nano-carriers toxicity is apparently hindering the extensive applications of nanotechnology in medical sciences. Many studies on the effects of nanomaterials in vitro and in vivo have been published, and revealed that nanomaterials including carbon nanotubes, fullerenes, quantum dots (for example CdS) and oxide nanoparticles (NPs) (for example ZnO, CuO and TiO2) exhibited various toxic effects on biological system. More importantly, they can cause lung inflammation, liver injury, kidney failure, or even fatality [1]. Compared with non-biodegradable nanomaterials, the same nano sized drug carriers prepared by biodegradable ones, such as albumin (Abraxane®) and phosphatides (Doxil®) used in human being approved by FDA, are fairly safe [2-4].

To read the full article Peer-reviewed Article PDF image

Author(s): Mingyuan Li, Zhiping Li, Zhenbo Yang and Xingguo Mei


Nanotoxicity, Physical Damage, Nanomaterials, Biodegradable NPs, harmaceutics,Molecular Drug Design,Alternative Medicines

Recommended Journals

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version